Woman examines the changes in the stock market at her office. The best dividend stocks to buy for July were selected by analyzing yield sustainability, dividend growth over time and fundamental business quality.
Getty
The first half of 2026 has tested investor patience. Geopolitical friction pushed energy prices to multi-year highs. Meanwhile, the S&P 500 has clawed back toward record territory, supported by strong AI-driven earnings and a Fed that has stayed cautious. Goldman Sachs recently raised its year-end S&P 500 target to 8,000. However, plenty of risks remain that could rattle markets.
Companies with durable, growing dividends have historically held up far better during volatility than the broader index. The best dividend stocks to buy for July include five companies that offer above-average yields, credible dividend growth histories and business models resilient enough to keep paying — and ideally growing — their distributions through the second half of 2026.
I selected the top dividend stocks to buy for July on three primary criteria:
Each company covers its dividend comfortably from operating cash flow. Consecutive years of dividend growth, or in some cases spanning decades, was also examined.
The picks below span multiple sectors offering natural diversification. Whether inflation stays elevated, rates ease or the energy market stabilizes, each of these names has a credible path forward.
AbbVie is one of the largest pharmaceutical companies. It’s also one of several companies that have raised their dividend for at least 50 consecutive years. Rinvoq and Skyrizi, AbbVie's two immunology successors to Humira, are both posting strong sales momentum. AbbVie also has a neuroscience pipeline gaining traction, including FDA approval milestones.
AbbVie just raised its full-year 2026 adjusted EPS guidance to $14.08–$14.28 after a Q1 beat, and the company’s operational revenue grew more than 12% year-over-year in that period. Despite the elevated GAAP P/E — a function of acquisition-related amortization — the forward multiple of roughly 15x is reasonable for a business of this quality. The dividend yield of around 3.3% may not be the highest listed, but the 53-year streak of consecutive increases and clear strategy for post-Humira growth make ABBV one of the most dependable income plays in large-cap healthcare. For income investors who also want capital appreciation upside, this is a name that delivers on both.
Chevron is one of only a handful of major oil companies with a record of raising its dividend for nearly four decades straight. The company produced record full-year output in 2025 at 3.7 million barrels of oil equivalent per day, and its 2026 quarterly dividend reflects a 4% raise to $1.78 per share. Chevron’s integrated business model — spanning upstream production, downstream refining and lower-carbon investments in hydrogen and lithium — provides a degree of insulation that pure-play E&P companies lack.
Chevron sits in an enviable position: elevated oil prices benefitted the upstream business while the company's balance sheet has remained strong enough to keep the dividend safe even at lower commodity prices. Management targets free cash flow growth of over 10% annually through 2030 at $70 oil — meaning the dividend doesn't depend on $90-plus Brent to stay intact. At under 4% yield and with 38 years of consecutive increases behind it, CVX is one of the cleanest dividend growth stories in energy.
Enbridge is North America's largest energy infrastructure company by any practical measure. It operates more than 17,000 miles of liquid pipelines, over 3,100 miles of natural gas gathering and processing pipelines, and a growing portfolio of renewable generation assets across Canada and the U.S. What makes Enbridge attractive is the nature of how it generates revenue: long-term, take-or-pay contracts that look more like utility cash flows than commodity-sensitive ones. The company has raised its dividend every year for over three decades, recently bumping it 3% for 2026, and management has reaffirmed guidance for adjusted EBITDA of $20.2–$20.8 billion this year.
Enbridge has a secured growth backlog of $39 billion, providing a clear line of sight to continued cash flow growth. The stock's approximately 5.1% yield is attractive and well-supported by distributable cash flow, not just earnings per share. First-quarter 2026 results beat analyst estimates, and the company's Debt-to-EBITDA of 5.0x sits comfortably within its target range. For investors who want midstream infrastructure exposure with a thick dividend check and minimal commodity price sensitivity, ENB is the cleanest option on the board.
Realty Income has paid uninterrupted monthly dividends since 1969 and announced 115 consecutive quarterly dividend increases as of June. The company owns a portfolio of over 15,500 commercial properties leased to nearly 1,800 tenants across 92 industries, operating primarily under long-term net lease agreements that shift operating costs to the tenant. As a REIT, AFFO per share is the metric that matters most for dividend sustainability, and Q1 2026 AFFO came in at $1.13 — up 6.6% year-over-year — comfortably covering the dividend payout.
Realty Income raised its full-year 2026 AFFO guidance to $4.41–$4.44 per share and lifted its investment volume target to $9.5 billion, signaling confidence in deal flow even in a higher-rate environment. Portfolio occupancy sits at a healthy 98.9%, and Q1 revenue of $1.55 billion beat forecasts by over 11%. The diversification across geographies adds resilience that many domestic-only REITs don't offer. For income-focused investors who prefer monthly distributions and the stability of a business backed by blue-chip tenants on long leases, Realty Income remains the gold standard in its category.
Altria owns some of the most defensively positioned consumer brands in America. Its Marlboro cigarettes command roughly 40% of the U.S. market by volume — a moat that has proven remarkably durable for decades despite secular volume declines. The company has offset falling cigarette shipment volumes through consistent pricing power and a pivot toward reduced-risk products. Altria beat Q1 2026 EPS estimates and reaffirmed full-year adjusted EPS guidance of $5.56–$5.72, representing about 7% growth at the midpoint.
Altria's nearly 6% dividend yield is the highest on this list, and unlike many high-yielding stocks, the payout is well-supported — the dividend cash payout ratio sits around 82%, and adjusted EPS growth is expected to continue at a mid-to-high single-digit rate for the next several years. The company's beta of just 0.51 makes it one of the lower-volatility plays in the large-cap universe, which matters when markets get choppy. The CEO transition in May introduces some uncertainty, but the business model's structural cash generation doesn't depend on any single executive. At about 15x forward earnings with a near-6% yield, this is one of the more compelling value-plus-income setups in the current market.
Dividend investing in 2026 is about finding durable businesses that will keep paying and growing their distributions no matter what the macro environment delivers. AbbVie offers pharma resilience and a 53-year dividend growth record; Chevron combines energy sector upside with four decades of consecutive increases; Enbridge delivers infrastructure-grade cash flow stability with a 5%-plus yield; Realty Income brings monthly dividends and nearly unmatched consistency in the REIT space; and Altria offers a rare combination of a sub-15x valuation, a near-6% yield, and predictable pricing power.
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。